

DSD Policy and Practice Adaptations in Response to COVID19

Peter Preko (MB ChB, MPH) CQUIN Director, ICAP at Columbia 25th June 2020




HIV LEARNING NETWORK The CQUIN Project for Differentiated Service Delivery

OUTLINE

- Overview of Differentiated Service Delivery
- DSD Implementation Progress leading up to COVID19
- COVID19 Mandated Changes to DSD Policy and Practice
- Key Questions/Challenges
- Conclusion

Differentiated Service Delivery is a clientcentered approach that simplifies and adapts HIV services across the cascade to reflect the preferences and expectations of groups of people living with HIV while reducing unnecessary burdens on the health system


DSD Is About The "How" Not The "What"



- Service Intensity
- Service Frequency
- Service Location
- Service Provider

Why Differentiated Service Delivery?

Much Progress Made, But More Needs to be Achieved




Why Differentiated Service Delivery? (2)



Different subpopulations have different needs

Why Differentiated Service Delivery? (3)

Different Clinical Categories of People on ART



Who Is a Clinically "Stable" Recipient of Care?


Clinically stable recipients of care are people on ART who are adherent to treatment and do not require frequent clinical consultations:

- ✓ Received ART for at least one year
- ✓No adverse drug reactions that require regular monitoring
- ✓No current illnesses, including malnutrition in children, mental health conditions or postpartum depression
- ✓ A good understanding of lifelong adherence
- ✓ Evidence of treatment success: two consecutive viral load measurements of <1,000 copies/ml, rising CD4 cell count or CD4 count > 200 cells/mm3

******These criteria are however changing in the context of COVID*

World Health Organization

Growing Evidence Base For Less Intensive DSD Models for "Stable" Recipients of Care



Benefits of DSD

If implemented properly and at scale, DSD has the potential to:

Improve quality

- Increase patient-centered care
- Improve adherence, retention, viral suppression
- Reduce overcrowding at health facilities
- Enhance patient and provider satisfaction

Improve efficiency in the health sector


- Expand the numbers on treatment in the context of plateauing resources
- Focus resources on the most needy recipients of care

OUTLINE

- Overview of Differentiated Service Delivery
- DSD Implementation Progress leading up to COVID19
- COVID19 Mandated Changes to DSD Policy and Practice
- Key Questions/Challenges
- Conclusion




CQUIN Learning Network



- Led by ICAP at Columbia University and funded by the Bill & Melinda Gates Foundation
- Platform for sharing DSD innovations and best practices, including community-based models
- Working with ministries of health, national networks of PLHIV and PEPFAR implementing partners
- Strong collaboration with national networks of PLHIV for community engagement

The CQUIN Dashboard





Coverage



RED	ORANGE	YELLOW	LIGHT GREEN	DARK GREEN
Early or preliminary stages of planning and development; Useful in identifying next steps to take in the scale-up process	Work has begun and the initial efforts are ongoing; Highlights areas that can prioritized for improvement	Efforts have resulted in measurable progress, such as a draft for review or achievement of more than 25% progress to a target	Considerable progress has been made, resulting in over 50% progress to a target or working systems only in need of finalization	Achievement of a highly-evolved implementation of the domain; Further improvements and refinements can be made as needed


Significant Progress in DSD Implementation

CQUIN Dashboard 2018													
	Policies	Guidelines	Diversity	Scale-up Plan	Coordination	Community Eng	Training	SOPs	M&E System	Facility Coverag	Patient Coverag	Quality	Impact
Cote d'Ivoire													
Eswatini													
Ethiopia													
Kenya													
Malawi													
Mozambique													
South Africa													
Tanzania													
Uganda													
Zambia													
Zimbabwe													
CQUIN Dashboard 2019													
	Policies	Cuidalinas	Diversity	Scale-un Plan	Coordination	Community Eng	Training	SOPs	M&E System	Eacility Coverag	Datiant Courses	Quality	Impact
	Folicies	Guidelines	Diversity	Scale-up Flan	coordination	continuity Eng	manning	5015	Wide bystein	Facility Coverag	Patient Coverag	Quanty	inipact
Cote d'Ivoire	Policies	Guidelines	Diversity	Scale-up Flan	coordination		i annig	5015	Mar System	Facility Coverag	Patient Coverag	Quanty	impact
	Folicies	Guidelines	Diversity				in anning		inde bystem		Patient Coverag	Quanty	impact
Cote d'Ivoire		Guidelines	Diversity								Patient Coverag	Quanty	
Cote d'Ivoire Eswatini											Patient Coverag	Quanty	
Cote d'Ivoire Eswatini Ethiopia													
Cote d'Ivoire Eswatini Ethiopia Kenya											Patient Coverag		
Cote d'Ivoire Eswatini Ethiopia Kenya Malawi													
Cote d'Ivoire Eswatini Ethiopia Kenya Malawi Mozambique													
Cote d'Ivoire Eswatini Ethiopia Kenya Malawi Mozambique South Africa													
Cote d'Ivoire Eswatini Ethiopia Kenya Malawi Mozambique South Africa Tanzania													

OUTLINE

- Overview of Differentiated Service Delivery
- DSD Implementation Progress leading up to COVID19
- COVID19 Mandated Changes to DSD Policy and Practice
- Challenges and Way forward
- Conclusion

Considerations for DSD and Covid19 Response



Key DSD Policy & Practice Changes in Response to COVID19

- Relaxation of eligibility criteria for DSD
- Provision of longer multi-month dispensing
- Expansion and modifications to community-based DSD models
- Deprioritizing routine viral load monitoring


Relaxation of Eligibility Criteria for Less-Intensive DSD Models

- Suppressed viral load no longer a requirement for DSD
- Newly initiated on ART can now get MMD in some countries
- Patient with unsuppressed viral load can get MMD while receiving remote adherence counseling
- Patients with advanced HIV Disease can also get MMD
- Children, pregnant and breastfeeding women can now receive MMD


Longer Multi-month Dispensing Intervals

- COVID-19 led to rapid adoption of longer refills in some countries
- Some countries moved quickly to adopt or scale up 6-MMD
- Rapid adoption of 3-MMD for countries at the DSD planning phase
- Community ART Groups that were receiving monthly refills are now receiving 3-MMD

Defaulter Rate and 3-MMD Coverage in Mozambique



3-MMD and CAG Coverage



Source: MOH Mozambique


Changes to Community-based DSD Models

- Community-based DSD models expanded to include home delivery of ART
- Elderly and people with pre-existing conditions being offered home-delivery of ART
- Community-based group models have been discouraged from having group meetings

Deprioritizing Routine Viral Load Monitoring

- Routine VL monitoring has been suspended in some countries
- VL monitoring for clients in community-based models suspended
- VL not required for enrollment into 3-MMD
- Targeted VL for recipients of care suspected of failing treatment

Disruptions In Services Due To COVID19



Source: WHO HIV/HEP/STI COVID-19 Questionnaire

Uptake of Routine Viral Load During COVID19: Afya Pwani Project- Kenya

1316 1355 Jan Feb Mar Apr May Kilifi Kwale Mombasa Taita Taveta

Viral Load Uptake Jan-May 2020

The CQUIN Project

AFYA PWANI Project - Kenya

OUTLINE

- Overview of Differentiated Service Delivery
- DSD Implementation Progress Leading up to COVID19
- COVID19 Mandated Changes to DSD Policy and Practice
- Key Questions/Challenges

Key Questions/Challenges

- Will these challenges be sustained beyond COVID-19?
- Concern of ARV supply interruption
- M&E issues in the era of COVID-19: Countries still figuring out how to effectively document and monitor ART delivery in this era
 - Uganda created a make shift register to collect and harmonize data
- What will be the impact of suspending routine VL?
- Is it possible to ensure people on ART receive routine laboratory monitoring while protecting them from COVID?
- What about diagnostic services for people with advanced HIV disease?

Thank You